Fast results hybrid capture assay and associated strategically truncated probes
First Claim
Patent Images
1. A strategically truncated polynucleotide probe at least 1 kilobase in length and sharing 70% or more identity with a sequence selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO;
17, SEQ ID NO;
104 to SEQ ID NO;
110, SEQ ID NO;
116, and full-length complements thereof, wherein;
said polynucleotide probe comprises at least one sequence having from 70% to 100% complementarity to at least 100 contiguous bases of each of L1, L2, E1, E2, E4, E6, and E7 of a HPV nucleic acid selected from the group consisting of SEQ ID NO;
1 to SEQ ID NO;
17, SEQ ID NO;
104 to SEQ ID NO;
110, SEQ ID NO;
116; and
wherein said polynucleotide probe does not contain any sequences of at least 100 contiguous bases having about 70% to 100% complementarity to at least 100 contiguous bases of SEQ ID NO;
18 to SEQ ID NO;
43 and full-length complements thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
Strategically truncated probes specific for high-risk HPV nucleic acids, and methods for making and using the same, are disclosed herein. The disclosed probes, and methods of use thereof, permit fast and reliable detection of human papillomavirus in clinical samples without significant cross-reaction.
214 Citations
13 Claims
-
1. A strategically truncated polynucleotide probe at least 1 kilobase in length and sharing 70% or more identity with a sequence selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO;
17, SEQ ID NO;
104 to SEQ ID NO;
110, SEQ ID NO;
116, and full-length complements thereof, wherein;said polynucleotide probe comprises at least one sequence having from 70% to 100% complementarity to at least 100 contiguous bases of each of L1, L2, E1, E2, E4, E6, and E7 of a HPV nucleic acid selected from the group consisting of SEQ ID NO;
1 to SEQ ID NO;
17, SEQ ID NO;
104 to SEQ ID NO;
110, SEQ ID NO;
116; andwherein said polynucleotide probe does not contain any sequences of at least 100 contiguous bases having about 70% to 100% complementarity to at least 100 contiguous bases of SEQ ID NO;
18 to SEQ ID NO;
43 and full-length complements thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
- 1 to SEQ ID NO;
Specification